Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary extracted from

  • Al-Masoudi, N.A.; Mahdi, K.M.; Abdul-Rida, N.A.; Saeed, B.A.; Engel, M.
    A new pregnenolone analogues as privileged scaffolds in inhibition of CYP17 hydroxylase enzyme. Synthesis and in silico molecular docking study (2015), Steroids, 100, 52-59.
    View publication on PubMed

Cloned(Commentary)

EC Number Cloned (Comment) Organism
1.14.14.19 expressed in Escherichia coli Homo sapiens

Inhibitors

EC Number Inhibitors Comment Organism Structure
1.14.14.19 (2Z)-3-[3-hydroxy-4-[([[(3alpha)-3-methyl-20-oxopregn-5-en-3-yl]oxy]carbonyl)oxy]phenyl]prop-2-enoic acid 41.34% inhibition at 0.01 mM Homo sapiens
1.14.14.19 (2Z)-3-[4-methoxy-3-[([[(3alpha)-3-methyl-20-oxopregn-5-en-3-yl]oxy]carbonyl)oxy]phenyl]prop-2-enoic acid 43.27% inhibition at 0.01 mM Homo sapiens
1.14.14.19 (2Z)-3-[4-[([[(3alpha)-3-methyl-20-oxopregn-5-en-3-yl]oxy]carbonyl)oxy]phenyl]prop-2-enoic acid 45.5% inhibition at 0.01 mM Homo sapiens
1.14.14.19 17-((1-(2-(trifluoromethyl)-1H-benzimidazol-5-yl)imino)ethyl)-5-androsten-3beta-ol 78.61% inhibition at 0.01 mM Homo sapiens
1.14.14.19 17-((1-(6-methoxybenzothiazol-2-yl)imino)ethyl)-5-androsten-3beta-ol 81.99% inhibition at 0.01 mM Homo sapiens
1.14.14.19 17-(1-(n-hexylamino)-1-hydroxyethyl)-5-androsten-3beta-ol 62.52% inhibition at 0.01 mM Homo sapiens
1.14.14.19 2-((1-(5-androsten-3beta-ol-17-yl)ethylidene)amino)benzamide 39.38% inhibition at 0.01 mM Homo sapiens
1.14.14.19 3,5-dihydroxy-4-[([[(3alpha)-3-methyl-20-oxopregn-5-en-3-yl]oxy]carbonyl)oxy]benzoic acid 83.21% inhibition at 0.01 mM Homo sapiens
1.14.14.19 4-((1-(5-androsten-3beta-ol-17-yl)ethylidene)amino)-3-methoxybenzoic acid 43.34% inhibition at 0.01 mM Homo sapiens
1.14.14.19 4-((1-(5-androsten-3beta-ol-17-yl)ethylidene)amino)-N-(4-methylpyrimidin-2-yl)benzenesulfonamide 56.23% inhibition at 0.01 mM Homo sapiens
1.14.14.19 4-((1-(5-androsten-3beta-ol-17-yl)ethylidene)amino)-N-(isoxazol-3-yl)benzenesulfonamide 81.78% inhibition at 0.01 mM Homo sapiens
1.14.14.19 4-((1-(5-androsten-3beta-ol-17-yl)ethylidene)amino)-N-(pyrimidin-2-yl)benzenesulfonamide 16.27% inhibition at 0.01 mM Homo sapiens
1.14.14.19 4-((1-(5-androsten-3beta-ol-17-yl)ethylidene)amino)benzenesulfonamide 57.1% inhibition at 0.01 mM; 78.84% inhibition at 0.01 mM Homo sapiens
1.14.14.19 4-((1-(5-androsten-3beta-ol-17-yl)ethylidene)amino)benzenesulfonic acid 8.37% inhibition at 0.01 mM Homo sapiens
1.14.14.19 4-((1-(5-androsten-3beta-ol-17-yl)ethylidene)amino)benzoic acid 49.21% inhibition at 0.01 mM Homo sapiens
1.14.14.19 abiraterone 85.38% inhibition at 0.01 mM Homo sapiens
1.14.14.19 N-(4,6-dimethylpyrimidin-2-yl)-4-((1-(5-androsten-3beta-ol-17-yl)ethylidene)amino)benzene sulfonamide 48.37% inhibition at 0.01 mM Homo sapiens
1.14.14.19 N-(4-((1-(5-androsten-3beta-ol-17-yl)ethylidene)amino)phenyl)acetamide 40.02% inhibition at 0.01 mM Homo sapiens
1.14.14.19 sulfamerazine 53.44% inhibition at 0.01 mM Homo sapiens
1.14.14.19 sulfamethazine 49.34% inhibition at 0.01 mM Homo sapiens
1.14.14.19 sulfamethoxazole 55.23% inhibition at 0.01 mM Homo sapiens
1.14.14.19 TOK-001 also named galeterone Homo sapiens
1.14.14.19 VN/85-1
-
 Homo sapiens

Natural Substrates/ Products (Substrates)

EC Number Natural Substrates Organism Comment (Nat. Sub.) Natural Products Comment (Nat. Pro.) Rev. Reac.
1.14.14.19 pregnenolone + [reduced NADPH-hemoprotein reductase] + O2 Homo sapiens
-
 17alpha-hydroxypregnenolone + [oxidized NADPH-hemoprotein reductase] + H2O
-
 ?
1.14.14.19 progesterone + [reduced NADPH-hemoprotein reductase] + O2 Homo sapiens
-
 17alpha-hydroxyprogesterone + [oxidized NADPH-hemoprotein reductase] + H2O
-
 ?

Organism

EC Number Organism UniProt Comment Textmining
1.14.14.19 Homo sapiens
-
-
-

Substrates and Products (Substrate)

EC Number Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
1.14.14.19 pregnenolone + [reduced NADPH-hemoprotein reductase] + O2
-
 Homo sapiens 17alpha-hydroxypregnenolone + [oxidized NADPH-hemoprotein reductase] + H2O
-
 ?
1.14.14.19 progesterone + [reduced NADPH-hemoprotein reductase] + O2
-
 Homo sapiens 17alpha-hydroxyprogesterone + [oxidized NADPH-hemoprotein reductase] + H2O
-
 ?

Synonyms

EC Number Synonyms Comment Organism
1.14.14.19 17alpha-hydroxylase-C17,20-lyase
-
 Homo sapiens
1.14.14.19 CYP17
-
 Homo sapiens

IC50 Value

EC Number IC50 Value IC50 Value Maximum Comment Organism Inhibitor Structure
1.14.14.19 0.000072
-
 at pH 7.4 and 37°C Homo sapiens abiraterone
1.14.14.19 0.00129
-
 at pH 7.4 and 37°C Homo sapiens 3,5-dihydroxy-4-[([[(3alpha)-3-methyl-20-oxopregn-5-en-3-yl]oxy]carbonyl)oxy]benzoic acid
1.14.14.19 0.00211
-
 at pH 7.4 and 37°C Homo sapiens 4-((1-(5-androsten-3beta-ol-17-yl)ethylidene)amino)-N-(isoxazol-3-yl)benzenesulfonamide
1.14.14.19 0.00238
-
 at pH 7.4 and 37°C Homo sapiens 17-((1-(6-methoxybenzothiazol-2-yl)imino)ethyl)-5-androsten-3beta-ol
1.14.14.19 0.00311
-
 at pH 7.4 and 37°C Homo sapiens 4-((1-(5-androsten-3beta-ol-17-yl)ethylidene)amino)benzenesulfonamide
1.14.14.19 0.00329
-
 at pH 7.4 and 37°C Homo sapiens 17-((1-(2-(trifluoromethyl)-1H-benzimidazol-5-yl)imino)ethyl)-5-androsten-3beta-ol
1.14.14.19 0.01859
-
 at pH 7.4 and 37°C Homo sapiens 17-(1-(n-hexylamino)-1-hydroxyethyl)-5-androsten-3beta-ol
1.14.14.19 0.0198
-
 at pH 7.4 and 37°C Homo sapiens 4-((1-(5-androsten-3beta-ol-17-yl)ethylidene)amino)benzenesulfonamide
1.14.14.19 0.0222
-
 at pH 7.4 and 37°C Homo sapiens (2Z)-3-[3-hydroxy-4-[([[(3alpha)-3-methyl-20-oxopregn-5-en-3-yl]oxy]carbonyl)oxy]phenyl]prop-2-enoic acid
1.14.14.19 0.0247
-
 at pH 7.4 and 37°C Homo sapiens (2Z)-3-[4-[([[(3alpha)-3-methyl-20-oxopregn-5-en-3-yl]oxy]carbonyl)oxy]phenyl]prop-2-enoic acid
1.14.14.19 0.0268
-
 at pH 7.4 and 37°C Homo sapiens N-(4,6-dimethylpyrimidin-2-yl)-4-((1-(5-androsten-3beta-ol-17-yl)ethylidene)amino)benzene sulfonamide
1.14.14.19 0.0342
-
 at pH 7.4 and 37°C Homo sapiens sulfamerazine